Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E HERZOG

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
Oncotarget|August 4, 2016
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsJ Andrew Livingston, Kenneth R Hess, Aung Naing, et al.
Cancer|December 21, 2006
Chemotherapy response is an important predictor of local recurrence in Ewing sarcomaPatrick P Lin, Norman Jaffe, Cynthia E Herzog, et al.
Journal of Pediatric Surgery|December 11, 2012
Primary malignant pancreatic neoplasms in children and adolescents: a 20 year experienceYesenia Rojas, Carla L Warneke, Chetan A Dhamne, et al.
ESMO Open|October 25, 2023
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I studyS Phadnis, X Wang, N C Daw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium studyRochelle Bagatell, Lia Gore, Merrill J Egorin, et al.
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Pediatric Blood & Cancer|July 1, 2016
A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcomaPeter M Anderson, Stefan S Bielack, Richard G Gorlick, et al.
Scientific Reports|October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesVivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Pediatric Blood & Cancer|April 3, 2016
Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk MelanomaFariba Navid, Cynthia E Herzog, John Sandoval, et al.
Pediatric Blood & Cancer|May 12, 2018
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous systemPeter E Manley, Tanya Trippett, Amy A Smith, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Oncotarget|August 4, 2016
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsJ Andrew Livingston, Kenneth R Hess, Aung Naing, et al.
Cancer|December 21, 2006
Chemotherapy response is an important predictor of local recurrence in Ewing sarcomaPatrick P Lin, Norman Jaffe, Cynthia E Herzog, et al.
Journal of Pediatric Surgery|December 11, 2012
Primary malignant pancreatic neoplasms in children and adolescents: a 20 year experienceYesenia Rojas, Carla L Warneke, Chetan A Dhamne, et al.
ESMO Open|October 25, 2023
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I studyS Phadnis, X Wang, N C Daw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium studyRochelle Bagatell, Lia Gore, Merrill J Egorin, et al.
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Pediatric Blood & Cancer|July 1, 2016
A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcomaPeter M Anderson, Stefan S Bielack, Richard G Gorlick, et al.
Scientific Reports|October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesVivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Pediatric Blood & Cancer|April 3, 2016
Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk MelanomaFariba Navid, Cynthia E Herzog, John Sandoval, et al.
Pediatric Blood & Cancer|May 12, 2018
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous systemPeter E Manley, Tanya Trippett, Amy A Smith, et al.
Pageof 17